ClinicalTrials.gg

Program

plozasiran

Also written as “Plozasiran Injection”, “ARO-APOC3” and “Plozasiran”.

Its studies are mostly in Hypertriglyceridemia · Dyslipidemias · Hyperlipoproteinemia Type I, led by 2 companies.

Furthest: phase 3, since Oct 11, 202112 company-led studies, 2 open or runningNext primary completion: Jul 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Arrowhead Pharmaceuticals102 open or runningphase 3since Oct 11, 2021Dec 19, 2018Jul 2028phase 3 · NCT06822790
Visirna Therapeutics HK20 open or runningphase 3since May 31, 2023Feb 14, 2023none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 19, 2018First study: phase 1 study in HypertriglyceridemiaNew to Arrowhead PharmaceuticalsArrowhead Pharmaceuticals · NCT03783377 · 112 enrolled · Australia, Canada, New Zealand
  2. Jan 19, 2021Phase 2 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT04720534 · 229 enrolled · United States, Australia, Canada and more
  3. Aug 3, 2021Phase 2 study in Mixed DyslipidemiaArrowhead Pharmaceuticals · NCT04998201 · 353 enrolled · United States, Australia, Canada and more
  4. Oct 11, 2021Phase 3 study in Hyperlipoproteinemia Type IArrowhead Pharmaceuticals · NCT05089084 · 75 enrolled · United States, Argentina, Australia and more
  5. Jun 7, 2022Phase 2 study in DyslipidemiasArrowhead Pharmaceuticals · NCT05413135 · 418 enrolled · United States, Australia, Canada and more
  6. Feb 14, 2023Visirna Therapeutics HK's first study: phase 1 study in Healthy Adult VolunteersNew to Visirna Therapeutics HKVisirna Therapeutics HK · NCT05757596 · 24 enrolled · China
  7. May 31, 2023Phase 3 study in Familial hyperchylomicronemia syndromeVisirna Therapeutics HK · NCT05902598 · 37 enrolled · China
  8. Mar 29, 20243 phase 3 studies in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06347133, NCT06347016, NCT06347003
  9. Feb 7, 2025Phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06822790 · 710 enrolled · United States, Argentina, Australia and more
  10. Mar 12, 2025Phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06880770 · 288 planned · United States, Argentina, Austria and more

Ahead

  1. Jul 2028Primary completion: phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06822790
  2. Mar 2029Primary completion: phase 3 study in HypertriglyceridemiaArrowhead Pharmaceuticals · NCT06880770

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 12 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06880770Hypertriglyceridemia · United States, Argentina, Austria and more3RecruitingArrowhead PharmaceuticalsMar 2029288
NCT06822790Hypertriglyceridemia · United States, Argentina, Australia and more3Active, not recruitingArrowhead PharmaceuticalsJul 2028710
NCT06347133Hypertriglyceridemia · United States, Argentina, Australia and more3CompletedArrowhead PharmaceuticalsJun 1, 20261,456
NCT06347016Hypertriglyceridemia · United States, Argentina, Brazil and more3CompletedArrowhead PharmaceuticalsJun 17, 2026311
NCT06347003Hypertriglyceridemia · United States, Argentina, Australia and more3CompletedArrowhead PharmaceuticalsJun 12, 2026446
NCT05902598Familial hyperchylomicronemia syndrome · China3CompletedVisirna Therapeutics HKNov 26, 202437
NCT05757596Healthy Adult Volunteers · China1CompletedVisirna Therapeutics HKSep 25, 202324
NCT05413135Dyslipidemias · United States, Australia, Canada and more2CompletedArrowhead PharmaceuticalsSep 22, 2025418
NCT05089084Hyperlipoproteinemia Type I · United States, Argentina, Australia and more3CompletedArrowhead PharmaceuticalsApr 29, 202475
NCT04998201Mixed Dyslipidemia · United States, Australia, Canada and more2CompletedArrowhead PharmaceuticalsFeb 10, 2023353
NCT04720534Hypertriglyceridemia · United States, Australia, Canada and more2CompletedArrowhead PharmaceuticalsMar 9, 2023229
NCT03783377Hypertriglyceridemia · Australia, Canada, New Zealand1CompletedArrowhead PharmaceuticalsFeb 11, 2021112

How it is read

Names in the registry

  • “Plozasiran Injection”, 4 entries
  • “ARO-APOC3”, 4 entries
  • “Plozasiran”, 3 entries
  • “VSA001 injection”, 1 entry

Codes read as this program: VSA001.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
plozasiran (Arrowhead Pharmaceuticals): development program | ClinicalTrials.gg